Brain optimisation: GVS-111 increases Nerve Growth Factor (NGF) and Brain-Derived Neurotrophic Factor (BDNF). Critical for neuroplasticity and Long-Term Potentiation. Brain health gets a boost along with long-term memory.
Neuroprotection: GVS-111 prevents the release of excess glutamate in your brain. Glutamate is the brain’s primary excitatory neurotransmitter. When there’s a lack of oxygen in the brain, neutrons can’t receive glutamate. This leads to toxic levels of glutamate within brain cells and can result in neuron damage and death. Diminishing this neurotic overload with GVS is potent neuroprotection.
Brain waves: GVS-111 boosts Alpha and Beta brain wave activity. You become calmer and more creative. Its easier to get into a flow state where you make innovative and resourceful decisions. GVS-111 boosts brain health and function in several ways, but two in particular stand out. GVS-111 modulates AMPA and NMDA receptors and acetylcholine (ACh) transmission. GVS-111 boosts the level of cycloprolyglycine (CPG) in the brain. In so doing it optimises neurotransmitter function. GVS-111 has also been shown to modulate acetylcholine flow in the brain. Restoring harmony of glutamate and acetylcholine function not only protects your brain from damage, it can boost cognition, memory, learning, recall, mood and relieve anxiety. It increases Nerve Growth Factor (NGF), Brain-Derived Neurotrophoc Factor (BDNF) and mRNA. NGF and BDNF are directly related to neuroplasticity.
This ability to repair and even grow new brain cells can have profound implications. Particularly with someone with neurodegenerative brain damage like Parkinsons or Alzheimers. And even affecting Long-Term Potentiation needed for long term memory development. mRNA affects the expression of genes and intracellular communication in brain cells. This ongoing brain signalling and gene expression within brain cells is required for healthy cognition. One study conducted in Moscow showed long-term use of GVS-111
Modafinil (2-[(Diphenylmethyl) sulfinyl] acetamide, Provigil) is an FDA-approved medication with wake-promoting properties. Pre-clinical studies of modafinil suggest a complex profile of neurochemical and behavioral effects, distinct from those of amphetamine.
In addition, modafinil shows initial promise for a variety of off-label indications in psychiatry, including treatment-resistant depression, attention-deficit/hyperactivity disorder, and schizophrenia. Cognitive dysfunction may be a particularly important emerging treatment target for modafinil, across these and other neuropsychiatric disorders.
Modafinil exhibits robust effects on catecholamines, serotonin, glutamate, gamma amino-butyric acid, orexin, and histamine systems in the brain. Many of these effects may be secondary to catecholamine effects, with some selectivity for cortical over subcortical sites of action.
Moreover, modafinil (at well-tolerated doses) improves function in several cognitive domains, including working memory and episodic memory, and other processes dependent on prefrontal cortex and cognitive control. These effects are observed in rodents, healthy adults, and across several psychiatric disorders. Furthermore, modafinil appears to be well-tolerated, with a low rate of adverse events and a low liability to abuse.
Modafinil has a number of neurochemical actions in the brain, which may be related to primary effects on catecholaminergic systems. These effects are in general advantageous for cognitive processes.